J&J opts in for Idorsia's hypertension candidate

Idorsia Ltd. (SIX:IDIA) said the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) exercised its option to co-develop and commercialize aprocitentan (ACT-132577) and its derivatives.

Idorsia will be responsible for Phase III development and regulatory submission of aprocitentan to treat hypertension that is not controlled by at least three anti-hypertensive drugs, with costs shared equally by the partners. Janssen will have worldwide commercialization rights, and is responsible for developing the product in any additional indications...